Pacira to Report 2025 Financial Results on Thursday February 26, 2026
Pacira (Nasdaq: PCRX) will report fourth-quarter and full-year 2025 financial results after U.S. market close on Thursday, February 26, 2026.
Rhea-AI Summary
Pacira (Nasdaq: PCRX) will report fourth-quarter and full-year 2025 financial results after U.S. market close on Thursday, February 26, 2026. A live conference call and webcast will follow at 4:30 p.m. ET.
Investors can pre-register for the call to receive dial-in details and a PIN; a live audio webcast will be available on the company’s Events page at investor.pacira.com. A replay of the webcast will be available on the website for approximately two weeks after the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PCRX
On Feb 13, the first trading day after this news, PCRX closed 1.49% above the previous close.
Data tracked by StockTitan Argus for the Feb 13 session.
Key Figures
- Earnings release date
- February 26, 2026
- Fourth quarter and full-year 2025 results after market close
- Fiscal year-end
- December 31, 2025
- Year ended December 31, 2025 for reported results
- Conference call time
- 4:30 p.m. ET
- Earnings conference call start time on February 26, 2026
- Webcast replay duration
- Approximately two weeks
- Replay availability period following the earnings call
Historical Context
-
Inducement stock options and RSUs granted to new employees under plan.
-
Addition of experienced clinical development executive to Board of Directors.
-
LG Chem agreement to commercialize EXPAREL in select Asia-Pacific markets.
-
Preliminary 2025 revenue and product sales figures with share repurchase details.
-
J.P. Morgan Healthcare Conference presentation with webcast access for investors.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Pacira BioSciences, Inc. Christian Pedetti, (973) 254-4387 Christian.Pedetti@pacira.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.